Japanese Nationwide PCI (J-PCI) Registry Annual Report 2019: patient demographics and in-hospital outcomes

the J-PCI Registry Investigators

doi:10.1007/s12928-021-00832-0

Japanese Nationwide PCI (J-PCI) Registry Annual Report 2019: patient demographics and in-hospital outcomes

the J-PCI Registry Investigators

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

本文言語	英語
ページ（範囲）	243-247
ページ数	5
ジャーナル	Cardiovascular Intervention and Therapeutics
巻	37
号	2
DOI	https://doi.org/10.1007/s12928-021-00832-0
出版ステータス	出版済み - 04-2022
外部発表	はい

All Science Journal Classification (ASJC) codes

放射線学、核医学およびイメージング
循環器および心血管医学

文献へのアクセス

10.1007/s12928-021-00832-0

他のファイルとリンク

引用スタイル

@article{ca6fbcf0fe1a4432aae2928822cca845,

title = "Japanese Nationwide PCI (J-PCI) Registry Annual Report 2019: patient demographics and in-hospital outcomes",

author = "\{the J-PCI Registry Investigators\} and Hirohiko Ando and Kyohei Yamaji and Shun Kohsaka and Hideki Ishii and Hideki Wada and Sumio Yamada and Mitsuaki Sawano and Taku Inohara and Yohei Numasawa and Yuji Ikari and Tetsuya Amano",

note = "Funding Information: K.Y. reports investigator-initiated grant funding from Abbott. S.K. reports investigator-initiated grant funding from Bayer and Daiichi Sankyo and personal fees from Bristol-Myers Squibb. H.I. receives lecture fees from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, MSD, Otsuka, and Pfizer. T.I. has a research grant from Boston Scientific. T.A. receives lecture fees from Astellas Pharma, AstraZeneca, Bayer, Daiichi Sankyo, and Bristol-Myers Squibb. The rest of the authors have no conflict of interest to report. Funding Information: The authors would like to thank all the members of the CVIT, the CVIT secretariat, and the patients who were included in the analysis.",

year = "2022",

month = apr,

doi = "10.1007/s12928-021-00832-0",

language = "English",

volume = "37",

pages = "243--247",

journal = "Cardiovascular Intervention and Therapeutics",

issn = "1868-4300",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Japanese Nationwide PCI (J-PCI) Registry Annual Report 2019

T2 - patient demographics and in-hospital outcomes

AU - the J-PCI Registry Investigators

AU - Ando, Hirohiko

AU - Yamaji, Kyohei

AU - Kohsaka, Shun

AU - Ishii, Hideki

AU - Wada, Hideki

AU - Yamada, Sumio

AU - Sawano, Mitsuaki

AU - Inohara, Taku

AU - Numasawa, Yohei

AU - Ikari, Yuji

AU - Amano, Tetsuya

N1 - Funding Information: K.Y. reports investigator-initiated grant funding from Abbott. S.K. reports investigator-initiated grant funding from Bayer and Daiichi Sankyo and personal fees from Bristol-Myers Squibb. H.I. receives lecture fees from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, MSD, Otsuka, and Pfizer. T.I. has a research grant from Boston Scientific. T.A. receives lecture fees from Astellas Pharma, AstraZeneca, Bayer, Daiichi Sankyo, and Bristol-Myers Squibb. The rest of the authors have no conflict of interest to report. Funding Information: The authors would like to thank all the members of the CVIT, the CVIT secretariat, and the patients who were included in the analysis.

PY - 2022/4

Y1 - 2022/4

UR - https://www.scopus.com/pages/publications/85122861663

UR - https://www.scopus.com/inward/citedby.url?scp=85122861663&partnerID=8YFLogxK

U2 - 10.1007/s12928-021-00832-0

DO - 10.1007/s12928-021-00832-0

M3 - Comment/debate

C2 - 35020153

AN - SCOPUS:85122861663

SN - 1868-4300

VL - 37

SP - 243

EP - 247

JO - Cardiovascular Intervention and Therapeutics

JF - Cardiovascular Intervention and Therapeutics

IS - 2

ER -